ArticleScientific reports2026
Cladosporium cladosporioides, endophyte of Strelitzia nicolai, as a new producer of Alternariol monomethyl ether with a potential cytotoxic activity.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of chemotherapy resistance is one of the challenges in cancer therapy, for the adaptability of cells to shield the normal targets, and expressing of efflux pumps to the normal drugs. Thus, searching for lead compounds of multiple targets activity in tumor cells, from novel endophytic fungi of medicinal plants, could be a distinctive approach for cancer chemotherapy. Cladosporium cladosporioides EFBL-025, endophyte of Strelitzia nicolai, was recognized for the first time as a potential Alternariol monomethyl ether (AME) producer (700.1 μg/l). This isolate was morphologically, and molecularly identified based on the ITS with accession # PX463714. The chemical identity of AME of C. cladosporioides was committed from the FT-IR, HPLC and LC-MS/MS. The molecular mass of the parent molecule was 274.2 m/z, with the same molecular fragmentation pattern of authentic AME, as revealed from LC-MS/MS. AME has a significant activity against the A549 (IC50 0.65 μg/ml), HepG-2 (IC50 1.2 μg/ml), MCF-7 cells (IC50 2.7 μg/ml), with selectivity index 28.2, 14.5 and 8.1 folds, respectively, compared to the OEC cells (IC50 18.4 μg/ml). The activity of AME was a slightly higher than Taxol towards the tested cells by 1.8 folds. The purified AME has a higher inhibitory activity for Topoisomerase II (IC50 value 5.7 μg/ml) and I (IC50 value 7.25 μg/ml), compared to Etoposide (15.02 μg/ml) and Topotecan (27.27 μg/ml). The maximum arrest of the MCF-7 cells growth was observed at G0-G1 phase by 73.9 %, with a potency to induce the apoptosis by 12 folds compared to the control cells, suggesting the interference with the machinery of cellular growth and protein synthesis prior to DNA replication. Upon treatment of MCF-7 cells with AME, the healing activity was reduced by 12.5 % after 24. From the docking analysis, the binding energy of AME with the αβ-tubulin vinca site was -8.3 kcal/mol, compared to -7.4 kcal/mol for vinblastine. The AME binding affinities with Topoisomerase I, IIα and IIβ were -7.3, -8.0, -8.3 kcal/mol, respectively, revealing the higher affinity for Topoisomerase II, as being consistent from the experimental analysis. Thus, this is the first reports exploring the metabolic potency of C. cladosporioides as AME producer, with the different cytotoxic insights.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.